# BMS-247550 Plus Carboplatin in Treating Patients With Recurrent or Refractory Solid Tumors

> **NCT00028561** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 45 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** ixabepilone
- **DRUG:** carboplatin
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00028561
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-10
- **Primary completion:** 2007-02
- **Final completion:** —
- **Target enrollment:** 45 (ACTUAL)
- **Why stopped:** Administratively complete.
- **Last updated:** 2013-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00028561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00028561, "BMS-247550 Plus Carboplatin in Treating Patients With Recurrent or Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00028561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*